Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in brain inhibitory neurons (24 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 72 | 0.91 |
| pathways Reactome | 3 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 11523
Sealed predictions
- DUSP8 in dopamine neurons, braak-0.04 (p 0.927) → -0.59 (p 0.092)receipt 11530
Swarm cases
receipt 11530: DUSP8 in dopamine neurons, braak
- power
- full sample -0.43 (p 0.077, n 18), 95% CI -0.75 to +0.05. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.48 (p 0.042, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.61 (p 0.0069, n 18). not the mix.
- skeptic
- leave-one-out range -0.58 to -0.36, sign flips 0; without severely affected donors -0.43 (p 0.077, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.68 (p 0.0019, n 18) vs -0.43 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DUSP8 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DUSP8 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.38 p 0.183 (needs p < 1.9e-4)
Receipts
loading the receipts